# Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations

> **NCT05267106** · PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 83 (actual)

## Conditions studied

- Glioblastoma
- Adult-type Diffuse Gliomas

## Interventions

- **DRUG:** Pemigatinib

## Key facts

- **NCT ID:** NCT05267106
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-05-20
- **Primary completion:** 2024-12-17
- **Final completion:** 2024-12-17
- **Target enrollment:** 83 (ACTUAL)
- **Why stopped:** Recruitment ceased after a pre-planned futility interim analysis indicated a low probability to confer a clinically meaningful improvement in objective response when compared to currently available therapies. There were no safety related concerns.
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267106, "Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05267106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*